pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics 2017; 102(3): 397–404.
83 83 Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacology & Therapeutics. 1997; 73(1): 67–74.
84 84 Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin‐treated patients: a HuGEnet systematic review and meta‐analysis. Genetics in Medicine: Official Journal of the American College of Medical Genetics 2005; 7(2): 97–104.
85 85 Consortium IWP, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine 2009; 360(8): 753–64.
86 86 Morin S, Loriot MA, Poirier JM, Tenneze L, Beaune PH, Funck‐Brentano C, et al. Is diclofenac a valuable CYP2C9 probe in humans? European Journal of Clinical Pharmacology 2001; 56 (11): 793–7.
87 87 Yasar U, Eliasson E, Forslund‐Bergengren C, Tybring G, Gadd M, Sjoqvist F, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. European Journal of Clinical Pharmacology 2001; 57 (10): 729–35.
88 88 Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac‐induced hepatitis. Pharmacogenetics 2000; 10(6): 511–8.
89 89 Sevilla‐Mantilla C, Ortega L, Agúndez JAG, Fernández‐Gutiérrez B, Ladero JM, Díaz‐Rubio M. Leflunomide‐induced acute hepatitis. Digestive & Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2004; 36(1): 82–4.
90 90de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)‐mephenytoin metabolism in Japanese. Molecular Pharmacology 1994; 46(4): 594–8.
91 91 Hulot J‐S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss‐of‐function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108(7): 2244–7.
92 92 Collet J‐P, Hulot J‐S, Pena A, Villard E, Esteve J‐B, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (London, England) 2009; 373 (9660): 309–17.
93 93 Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p‐450 polymorphisms and response to clopidogrel. The New England Journal of Medicine 2009; 360(4): 354–62.
94 94 Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. Journal of Hepatology 1994; 21(6): 1075–9.
95 95 Farrell GC, Liddle C. Drugs and the liver updated, 2002. Seminars in Liver Disease 2002; 22(2): 109–13.
96 96 Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. Journal of Pharmacology and Experimental Therapeutics 2003; 307(3): 906–22.
97 97 Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. Journal of Pharmacology and Experimental Therapeutics 2003; 306(1): 287–300.
98 98 Strassburg CP. Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics 2008; 9(6): 703–15.
99 99 Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP‐glucuronosyltransferase 1 in Gilbert’s syndrome. The New England Journal of Medicine 1995; 333 (18): 1171–5.
100 100 Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, et al. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metabolism and Disposition 2007; 35 (12): 2270–80.
101 101 Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP‐glucuronosyltransferases and irinotecan toxicity. Molecular Pharmacology 2002; 62(3): 446–50.
102 102 Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid‐induced hepatotoxicity. Clinical Pharmacology & Therapeutics 2011; 89(6): 911–4.
103 103 Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, van der Ven AJAM, Dekhuijzen R. Antituberculosis drug‐induced hepatotoxicity: concise up‐to‐date review. Journal of Gastroenterology & Hepatology 2008; 23(2): 192–202.
104 104 Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, et al. Effects of N‐acetyltransferase 2 (NAT2), CYP2E1 and Glutathione‐S‐transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. The Journal of Toxicological Sciences 2008; 33(2): 187–95.
105 105 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine 2006; 174(8): 935–52.
106 106 Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid‐induced hepatotoxicity in patients treated for latent tuberculosis. European Journal of Clinical Pharmacology 2006; 62(6): 423–9.
107 107 Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovascular Drug Reviews 2007; 25(1): 76–97.
108 108 Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AMD, et al. Nevirapine‐induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11(1): 23–31.
109 109 Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clinical Pharmacology & Therapeutics 2006; 79(4): 325–38.
110 110 Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenetics and Genomics 2007; 17(6): 403–15.
111 111 Chalasani N, Björnsson E. Risk factors for idiosyncratic drug‐induced liver injury. Gastroenterology 2010; 138(7): 2246–59.
112 112 Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug‐induced liver injury: interactions between drug properties and host factors. Journal of Hepatology 2015; 63(2): 503–14.
113 113 Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chemico‐Biological Interactions 2002; 142 (1–2): 7–23.
3 Drug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced Fatalities
Albert P. Li
In vitro ADMET LaboratoriesInc., 9221 Rumsey Road, Suite 8, Columbia, MD, USA
3.1 Introduction
Severe drug toxicity, especially drug‐induced liver toxicity (DILI), is a major challenge in drug development. The occurrence of severe drug toxicity for marketed drugs is a clear indication that the current paradigm for drug safety evaluation during development, namely, preclinical evaluation in multiple species of laboratory animals followed by phases I, II, and III clinical trials, does not always provide adequate information allowing the assessment of human drug safety. The role of metabolism and transport in the toxicity of 12 marketed drugs which have been withdrawn from the market or received black box warning concerning their toxicity